First joint guidelines of care for hidradenitis suppurativa issued by American Academy of Dermatology and Hidradenitis Suppurativa Foundation

The AAD and HSF published the first joint U.S. guidelines for hidradenitis suppurativa (HS), a condition affecting more than 3 million people, with 37 evidence-based recommendations. Biologics including adalimumab, bimekizumab, infliximab, and secukinumab are strongly recommended for moderate-to-severe HS; the groups also identify insurer-mandated step therapy as a barrier that delays appropriate care. The guidelines establish a treatment roadmap but the article reports no specific company or market reaction.

Analysis

The investable angle is not the guideline’s prevalence estimate; it is whether a professional-society standard changes payer behavior. The recommendations may give dermatologists stronger documentation for appeals against step therapy, potentially improving access to biologics for moderate-to-severe HS. That is a conditional tailwind for manufacturers of therapies specifically recommended here, including UCB’s bimekizumab and Novartis’s secukinumab, as well as adalimumab products. It is not evidence of a near-term sales step-up: the guidance is not binding on insurers, and the release provides no utilization, coverage, or prescribing data. Adalimumab’s competitive set also includes biosimilars, so broader use would not translate uniformly into branded revenue.

The second-order effect is a possible shift in treatment mix away from therapies the panel conditionally advises against or finds insufficiently supported, but the commercial impact is unclear without current HS prescribing and payer data. More referrals could also benefit dermatology clinics and procedural care, though no direct public-market exposure is established here.

Near term, expect limited fundamental impact absent payer-policy changes. Over 1–3 months, watch for coverage revisions, appeal outcomes, and prescribing trends; over 6–18 months, the durable question is whether earlier specialist diagnosis expands treated patients and biologic persistence. The contrarian point: a clearer standard of care may improve the case for treatment without solving the access bottleneck. The thesis weakens if major payers retain step edits or HS biologic starts fail to rise.

Key Decisions for Investors

• No immediate sector-wide trade: the announcement is clinical guidance, not a reimbursement mandate, and does not establish incremental prescriptions or revenue.
• Place UCB and Novartis on a conditional watchlist for HS-related uptake; seek company-specific HS sales, new-start or persistence data, and payer coverage changes before sizing a position. Do not infer that the full diagnosed population is commercially addressable.
• Monitor payer policy and dermatology prescribing over the next 1–3 months. Evidence of fewer step edits or faster biologic access would strengthen the positive case; unchanged restrictions or flat HS starts would falsify it.
• Treat any HS-related optimism in adalimumab as product-specific rather than a blanket branded-drug tailwind: verify the mix between originator and biosimilar products before drawing revenue conclusions.